Intravenous Drug Approved for Multidrug-Resistant HIV Infection

Logo: Theratechnologies (CNW Group/Theratechnologies Inc.)


The Food and Drug Administration (FDA) has approved Trogarzo™ (ibalizumab-uiyk; Theratechnologies and TaiMed Biologics) for the treatment of adults with HIV infection who are heavily treatment-experienced and whose infections are multidrug-resistant (MDR). It is intended for use with other antiretroviral medications.

Trogarzo, a humanized monoclonal antibody, is administered as an intravenous (IV) injection once every 14 days. Unlike other antiretroviral drugs, ibalizumab binds primarily to the second extracellular domain of the CD4+ T cell receptor, away from major histocompatibility complex II molecule binding sites. It prevents HIV from infecting CD4+ immune cells while preserving normal immunological function. Ibalizumab is active against HIV-1 resistant to all approved antiretroviral agents.

Vevazz Slim Line